Thierry Caus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thierry Caus has a total of 180 co-authors. Here are the top co-authors by number of shared publications:
Yuthiline Chabry
5 shared publications- Monique Bernard
Aix‐Marseille Univ, CNRS, CRMBM Marseille France
4 shared publications - Joseph Nader
Department of Cardiac Surgery, Amiens Picardy University Hospital, Amiens, France
3 shared publications - Youssef Bennis
UR UPJV 7517 MP3CV, CURS, University of Picardie Jules Verne, Amiens, 80054 France
3 shared publications A. Mouly
2 shared publicationsBertrand Marcheix
2 shared publications
Latest Publications
- Open Access
- 10 November 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (22) , 7970
Five-Year Mortality of Patients with Perioperative Myocardial Infarction After On-Pump Isolated or Combined Coronary Artery Bypass Graft Surgery: A Retrospective Propensity Score-Weighted Analysis
Background: Coronary artery bypass grafting (CABG) is a widely used procedure to treat coronary artery disease, performed either alone or in conjunction with other cardiac procedures. Perioperative myocardial infarction (pMI) remains a major complication after on-pump CABG and negatively influences survival. Its reported incidence varies with the applied definition, and little is known about its prognostic effect in combined surgeries. Objective: The aim of this study was to investigate the impact of pMI on 5-year survival after isolated or combined on-pump CABG. Methods: We retrospectively reviewed adult patients undergoing urgent or elective CABG with cardiopulmonary bypass at Amiens University Hospital between 2013 and 2017. Diagnosis of pMI followed the Fourth Universal Definition of myocardial infarction. The primary outcome was all-cause death within 5 years. Logistic regression and Cox proportional hazards analyses were performed, and inverse probability weighting based on propensity scores was used to minimize confounding. Results: Out of 712 patients, 112 (16%) experienced pMI. Five-year mortality was 32% in the pMI subgroup compared with 11% in those without pMI (p < 0.001). Before adjustment, pMI was associated with higher long-term mortality (HR = 2.62, 95%CI [1.73–4.00], p < 0.001). This effect persisted after weighting (HR = 2.43, 95% CI [1.56–3.78], p = 0.041). A landmark analysis excluding the first 30 postoperative days showed no significant link with later mortality (HR = 1.13, 95%CI [0.54–2.34], p = 0.74). Independent predictors of pMI included active smoking (OR = 2.24, 95% CI [1.36–3.69], p = 0.001) and prolonged bypass duration (>180 min) (OR = 2.57, 95% CI [1.19–5.34], p = 0.015). Conclusions: When defined by the Fourth Universal Definition, pMI was independently related to increased 5-year mortality following CABG, explained mainly by deaths occurring early after surgery.
- 10 November 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (22) , 7970
Open AccessFive-Year Mortality of Patients with Perioperative Myocardial Infarction After On-Pump Isolated or Combined Coronary Artery Bypass Graft Surgery: A Retrospective Propensity Score-Weighted Analysis
Background: Coronary artery bypass grafting (CABG) is a widely used procedure to treat coronary artery disease, performed either alone or in conjunction with other cardiac procedures. Perioperative myocardial infarction (pMI) remains a major complication after on-pump CABG and negatively influences survival. Its reported incidence varies with the applied definition, and little is known about its prognostic effect in combined surgeries. Objective: The aim of this study was to investigate the impact of pMI on 5-year survival after isolated or combined on-pump CABG. Methods: We retrospectively reviewed adult patients undergoing urgent or elective CABG with cardiopulmonary bypass at Amiens University Hospital between 2013 and 2017. Diagnosis of pMI followed the Fourth Universal Definition of myocardial infarction. The primary outcome was all-cause death within 5 years. Logistic regression and Cox proportional hazards analyses were performed, and inverse probability weighting based on propensity scores was used to minimize confounding. Results: Out of 712 patients, 112 (16%) experienced pMI. Five-year mortality was 32% in the pMI subgroup compared with 11% in those without pMI (p < 0.001). Before adjustment, pMI was associated with higher long-term mortality (HR = 2.62, 95%CI [1.73–4.00], p < 0.001). This effect persisted after weighting (HR = 2.43, 95% CI [1.56–3.78], p = 0.041). A landmark analysis excluding the first 30 postoperative days showed no significant link with later mortality (HR = 1.13, 95%CI [0.54–2.34], p = 0.74). Independent predictors of pMI included active smoking (OR = 2.24, 95% CI [1.36–3.69], p = 0.001) and prolonged bypass duration (>180 min) (OR = 2.57, 95% CI [1.19–5.34], p = 0.015). Conclusions: When defined by the Fourth Universal Definition, pMI was independently related to increased 5-year mortality following CABG, explained mainly by deaths occurring early after surgery.
- Open Access
- 29 August 2025
- Published by Elsevier in Annals of Thoracic Surgery Short Reports
- Vol. 4 (1) , 6-11
Frozen Elephant Trunk With Terumo Hybrid Plexus Prosthesis: A French Postmarket Longitudinal Study With Midterm Results
- 29 August 2025
- Published by Elsevier in Annals of Thoracic Surgery Short Reports
- Vol. 4 (1) , 6-11
Open AccessFrozen Elephant Trunk With Terumo Hybrid Plexus Prosthesis: A French Postmarket Longitudinal Study With Midterm Results
- Open Access
- 21 January 2025
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 142 (5) , 874-884
Cytokine Hemoadsorption versus Standard Care in Cardiac Surgery Using the Oxiris Membrane: The OXICARD Single-center Randomized Trial
Background: Cardiac surgery can lead to dysregulation with a proinflammatory state, resulting in adverse outcomes. Hemadsorption using the AN-69 membrane (Oxiris membrane, Baxter, USA) has the properties to chelate inflammatory cytokines. The authors hypothesized that in patients at high risk of inflammation, the use of the Oxiris membrane could decrease inflammation, preserve endothelial function, and improve postoperative outcomes. Methods: The authors conducted a randomized single-center study at Amiens University Hospital (Amiens, France). The study population consisted of adult patients admitted for scheduled cardiac surgery with an expected cardiopulmonary bypass (CPB) time greater than 90 min. The patients were allocated to either the standard group or the Oxiris group. The intervention consisted of using the Oxiris membrane on a Prismaflex device (Baxter, USA) at a blood flow rate of 450 ml/min during CPB. The primary outcome was the assessment of microcirculation on day 1 after surgery by measuring sublingual microcirculation using the microvascular flow index. Microvascular flow index reflects the microcirculation flow type and is graded from 0 to 3 as follows: 0, no flow; 1, intermittent flow; 2, sluggish flow; 3, continuous flow. The secondary outcome was a composite adverse outcome within 30 days after surgery. Cytokines and endothelial biomarkers were measured in all patients at different time points. An intention-to-treat analysis was performed. Results: From October 2019 to November 2022, the study included 70 patients. Two patients were excluded from the Oxiris group: one patient did not undergo surgery, and one procedure was performed under deep hypothermia. The microvascular flow index did not differ between groups on day 1 from baseline: difference (95% CI) Oxiris minus standard at –0.17 (–0.44 to 0.10); P = 0.2. The occurrence of a composite adverse outcome did not significantly differ between groups (14 [42%] for the Oxiris group vs. 12 [35%] for the standard group; P = 0.7). The overall variation in cytokines and angiopoietins did not significantly differ between groups. Conclusions: In patients scheduled for a cardiac surgery with prolonged CPB, the authors could not demonstrate the benefit on microcirculation and major cardiovascular events.
- 21 January 2025
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 142 (5) , 874-884
Open AccessCytokine Hemoadsorption versus Standard Care in Cardiac Surgery Using the Oxiris Membrane: The OXICARD Single-center Randomized Trial
Background: Cardiac surgery can lead to dysregulation with a proinflammatory state, resulting in adverse outcomes. Hemadsorption using the AN-69 membrane (Oxiris membrane, Baxter, USA) has the properties to chelate inflammatory cytokines. The authors hypothesized that in patients at high risk of inflammation, the use of the Oxiris membrane could decrease inflammation, preserve endothelial function, and improve postoperative outcomes. Methods: The authors conducted a randomized single-center study at Amiens University Hospital (Amiens, France). The study population consisted of adult patients admitted for scheduled cardiac surgery with an expected cardiopulmonary bypass (CPB) time greater than 90 min. The patients were allocated to either the standard group or the Oxiris group. The intervention consisted of using the Oxiris membrane on a Prismaflex device (Baxter, USA) at a blood flow rate of 450 ml/min during CPB. The primary outcome was the assessment of microcirculation on day 1 after surgery by measuring sublingual microcirculation using the microvascular flow index. Microvascular flow index reflects the microcirculation flow type and is graded from 0 to 3 as follows: 0, no flow; 1, intermittent flow; 2, sluggish flow; 3, continuous flow. The secondary outcome was a composite adverse outcome within 30 days after surgery. Cytokines and endothelial biomarkers were measured in all patients at different time points. An intention-to-treat analysis was performed. Results: From October 2019 to November 2022, the study included 70 patients. Two patients were excluded from the Oxiris group: one patient did not undergo surgery, and one procedure was performed under deep hypothermia. The microvascular flow index did not differ between groups on day 1 from baseline: difference (95% CI) Oxiris minus standard at –0.17 (–0.44 to 0.10); P = 0.2. The occurrence of a composite adverse outcome did not significantly differ between groups (14 [42%] for the Oxiris group vs. 12 [35%] for the standard group; P = 0.7). The overall variation in cytokines and angiopoietins did not significantly differ between groups. Conclusions: In patients scheduled for a cardiac surgery with prolonged CPB, the authors could not demonstrate the benefit on microcirculation and major cardiovascular events.
- Open Access
- 4 March 2024
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1381366
Editorial: Long-term durability of biological aortic valves
Editorial: Long-term durability of biological aortic valves
- 4 March 2024
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1381366
Open AccessEditorial: Long-term durability of biological aortic valves
Editorial: Long-term durability of biological aortic valves
- Open Access
- 28 August 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10, 1205770
Trends in SAVR with biological vs. mechanical valves in middle-aged patients: results from a French large multi-centric survey
Background/introduction: Currently, despite continued issues with durability ( 1), biological prosthetic valves are increasingly chosen over mechanical valves for surgical aortic valve replacement (SAVR) in adult patients of all ages, at least in Western countries. For younger patients, this choice means assuming the risks associated with a redo SAVR or valve-in-valve procedure.Purpose: To assess the use of mechanical vs. biological valve prostheses for SAVR relative to patient's age and implant time in a large population extracted from the French National Database EPICARD.Methods: Patients in EPICARD undergoing SAVR from 2007 to 2022 were included from 22 participating public or private centers chosen to represent a balanced representation of centre sizes and geographical discrepancies. Patients with associated pathology of the aorta (aneurysm or dissection) and requiring a vascular aortic prosthesis were excluded. Comparisons were made amongst centers, valve choice, implant date range, and patient age.Results: We considered 101,070 valvular heart disease patients and included 72,375 SAVR (mean age 71.4 ± 12.2 years). We observed a mechanical vs. biological prosthesis ratio (MBPR) of 0.14 for the overall population. Before 50 years old (y-o), MBPR was >1.3 (p < 0.001) while patients above 60 years-old received principally biological SAVR (p < 0.0001). Concerning patients between 50 and 60 years-old patients, MPVR was 1.04 (p = 0.03). Patients 50–60 years-old from the first and second study duration quartile (before August 2015) received preferentially mechanical SAVR (p < 0.001). We observed a shift towards more biological SAVR (p < 0.001) for patients from the third and fourth quartile to reach a MBPR at 0.43 during the last years of the series. Incidentally, simultaneous mitral valve replacement were more common in case of mechanical SAVR (p < 0.0001), while associated CABGs were more frequent in case of biological SAVR (p < 0.0001).Conclusion: In a large contemporary French patient population, real world practice showed a recent shift towards a lower age-threshold for biological SAVR as compared to what would suggest contemporary guidelines.
- 28 August 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10, 1205770
Open AccessTrends in SAVR with biological vs. mechanical valves in middle-aged patients: results from a French large multi-centric survey
Background/introduction: Currently, despite continued issues with durability ( 1), biological prosthetic valves are increasingly chosen over mechanical valves for surgical aortic valve replacement (SAVR) in adult patients of all ages, at least in Western countries. For younger patients, this choice means assuming the risks associated with a redo SAVR or valve-in-valve procedure.Purpose: To assess the use of mechanical vs. biological valve prostheses for SAVR relative to patient's age and implant time in a large population extracted from the French National Database EPICARD.Methods: Patients in EPICARD undergoing SAVR from 2007 to 2022 were included from 22 participating public or private centers chosen to represent a balanced representation of centre sizes and geographical discrepancies. Patients with associated pathology of the aorta (aneurysm or dissection) and requiring a vascular aortic prosthesis were excluded. Comparisons were made amongst centers, valve choice, implant date range, and patient age.Results: We considered 101,070 valvular heart disease patients and included 72,375 SAVR (mean age 71.4 ± 12.2 years). We observed a mechanical vs. biological prosthesis ratio (MBPR) of 0.14 for the overall population. Before 50 years old (y-o), MBPR was >1.3 (p < 0.001) while patients above 60 years-old received principally biological SAVR (p < 0.0001). Concerning patients between 50 and 60 years-old patients, MPVR was 1.04 (p = 0.03). Patients 50–60 years-old from the first and second study duration quartile (before August 2015) received preferentially mechanical SAVR (p < 0.001). We observed a shift towards more biological SAVR (p < 0.001) for patients from the third and fourth quartile to reach a MBPR at 0.43 during the last years of the series. Incidentally, simultaneous mitral valve replacement were more common in case of mechanical SAVR (p < 0.0001), while associated CABGs were more frequent in case of biological SAVR (p < 0.0001).Conclusion: In a large contemporary French patient population, real world practice showed a recent shift towards a lower age-threshold for biological SAVR as compared to what would suggest contemporary guidelines.
- 30 July 2023
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 119 (13) , 2355-2367
Aortic valve calcification is promoted by interleukin-8 and restricted through antagonizing CXC motif chemokine receptor 2
Aims: Inflammatory cytokines play a critical role in the progression of calcific aortic valve disease (CAVD), for which there is currently no pharmacological treatment. The aim of this study was to test the hypothesis that interleukin-8 (IL-8), known to be involved in arterial calcification, also promotes aortic valve calcification (AVC) and to evaluate whether pharmacologically blocking the IL-8 receptor, CXC motif chemokine receptor 2 (CXCR2), could be effective in preventing AVC progression. Methods and results: A cohort of 195 patients (median age 73, 74% men) diagnosed with aortic valve stenosis (severe in 16.9% of cases) were prospectively followed by CT for a median time of 2.6 years. A Cox proportional hazards regression analysis indicated that baseline IL-8 serum concentrations were associated with rapid progression of AVC, defined as an annualized change in the calcification score by CT ≥ 110 AU/year, after adjustment for age, gender, bicuspid anatomy, and baseline disease severity. In vitro, exposure of primary human aortic valvular interstitial cells (hVICs) to 15 pg/mL IL-8 induced a two-fold increase in inorganic phosphate (Pi)-induced calcification. IL-8 promoted NFκB pathway activation, MMP-12 expression, and elastin degradation in hVICs exposed to Pi. These effects were prevented by SCH527123, an antagonist of CXCR2. The expression of CXCR2 was confirmed in hVICs and samples of aortic valves isolated from patients with CAVD, in which the receptor was mainly found in calcified areas, along with MMP-12 and a degraded form of elastin. Finally, in a rat model of chronic kidney disease-associated CAVD, SCH527123 treatment (1 mg/kg/day given orally for 11 weeks) limited the decrease in aortic cusp separation, the increase in maximal velocity of the transaortic jet, and the increase in aortic mean pressure gradient measured by echocardiography, effects that were associated with a reduction in hydroxyapatite deposition and MMP-12 expression in the aortic valves. Conclusion: Overall, these results highlight, for the first time, a significant role for IL-8 in the progression of CAVD by promoting calcification via a CXCR2- and MMP-12-dependent mechanism that leads to elastin degradation, and identify CXCR2 as a promising therapeutic target for the treatment of CAVD.
- 30 July 2023
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 119 (13) , 2355-2367
Aortic valve calcification is promoted by interleukin-8 and restricted through antagonizing CXC motif chemokine receptor 2
Aims: Inflammatory cytokines play a critical role in the progression of calcific aortic valve disease (CAVD), for which there is currently no pharmacological treatment. The aim of this study was to test the hypothesis that interleukin-8 (IL-8), known to be involved in arterial calcification, also promotes aortic valve calcification (AVC) and to evaluate whether pharmacologically blocking the IL-8 receptor, CXC motif chemokine receptor 2 (CXCR2), could be effective in preventing AVC progression. Methods and results: A cohort of 195 patients (median age 73, 74% men) diagnosed with aortic valve stenosis (severe in 16.9% of cases) were prospectively followed by CT for a median time of 2.6 years. A Cox proportional hazards regression analysis indicated that baseline IL-8 serum concentrations were associated with rapid progression of AVC, defined as an annualized change in the calcification score by CT ≥ 110 AU/year, after adjustment for age, gender, bicuspid anatomy, and baseline disease severity. In vitro, exposure of primary human aortic valvular interstitial cells (hVICs) to 15 pg/mL IL-8 induced a two-fold increase in inorganic phosphate (Pi)-induced calcification. IL-8 promoted NFκB pathway activation, MMP-12 expression, and elastin degradation in hVICs exposed to Pi. These effects were prevented by SCH527123, an antagonist of CXCR2. The expression of CXCR2 was confirmed in hVICs and samples of aortic valves isolated from patients with CAVD, in which the receptor was mainly found in calcified areas, along with MMP-12 and a degraded form of elastin. Finally, in a rat model of chronic kidney disease-associated CAVD, SCH527123 treatment (1 mg/kg/day given orally for 11 weeks) limited the decrease in aortic cusp separation, the increase in maximal velocity of the transaortic jet, and the increase in aortic mean pressure gradient measured by echocardiography, effects that were associated with a reduction in hydroxyapatite deposition and MMP-12 expression in the aortic valves. Conclusion: Overall, these results highlight, for the first time, a significant role for IL-8 in the progression of CAVD by promoting calcification via a CXCR2- and MMP-12-dependent mechanism that leads to elastin degradation, and identify CXCR2 as a promising therapeutic target for the treatment of CAVD.
- Open Access
- 24 March 2023
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 179, 18-29
Indoxyl-sulfate activation of the AhR- NF-κB pathway promotes interleukin-6 secretion and the subsequent osteogenic differentiation of human valvular interstitial cells from the aortic valve
- 24 March 2023
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 179, 18-29
Open AccessIndoxyl-sulfate activation of the AhR- NF-κB pathway promotes interleukin-6 secretion and the subsequent osteogenic differentiation of human valvular interstitial cells from the aortic valve
- 24 December 2020
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 60 (1) , 191-193
Frozen elephant trunk infection: to defrost or to debranch?
Infections of frozen elephant trunk hybrid prosthesis (HP) are not well documented in the literature and their management is not standardized yet. We report herein the case of a 59-year-old patient who benefited from a Thoraflex™ HP aortic arch replacement for an acute type A aortic dissection. He presented a year later with a Staphylococcus aureus infection of the proximal part of this prosthesis. We performed a replacement of the proximal compound of the HP accompanied by a complete debranching of the 3 supra-aortic vessels with an inter-carotidal retro-oesophageal bypass. As we left in situ the endovascular graft within the descending aorta, a life-long antibiotic therapy was introduced. The postoperative follow-up was uneventful, and the patient discharged home 2 weeks after his surgery. As an alternative to a more radical redo surgery with major risk, a hybrid medical and surgical treatment of infected frozen elephant trunk could be considered.
- 24 December 2020
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 60 (1) , 191-193
Frozen elephant trunk infection: to defrost or to debranch?
Infections of frozen elephant trunk hybrid prosthesis (HP) are not well documented in the literature and their management is not standardized yet. We report herein the case of a 59-year-old patient who benefited from a Thoraflex™ HP aortic arch replacement for an acute type A aortic dissection. He presented a year later with a Staphylococcus aureus infection of the proximal part of this prosthesis. We performed a replacement of the proximal compound of the HP accompanied by a complete debranching of the 3 supra-aortic vessels with an inter-carotidal retro-oesophageal bypass. As we left in situ the endovascular graft within the descending aorta, a life-long antibiotic therapy was introduced. The postoperative follow-up was uneventful, and the patient discharged home 2 weeks after his surgery. As an alternative to a more radical redo surgery with major risk, a hybrid medical and surgical treatment of infected frozen elephant trunk could be considered.
- 3 November 2020
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 59 (2) , 458-466
The frozen elephant trunk technique in an emergency: THORAFLEX French National Registry offers new insights
OBJECTIVES: Our goal was to study the immediate outcome after an emergency frozen elephant trunk procedure with a Thoraflex™ Hybrid prosthesis (THP) in patients included in the EPI-Flex national registry and operated on in 21 French centres. METHODS: All patients operated on in France between April 2016 and April 2019 for acute aortic syndromes and who had an frozen elephant trunk procedure with a THP were included in the study. The main end point was in-hospital mortality. The secondary end point was neuromorbidity, including paraplegia. The evolution of the main end point was monitored using a variable life-adjusted display graph with cumulative sum derivatives in order to stop inclusions in case the observed mortality became out of range compared to an expected mortality between 15% and 20%. RESULTS: Enrolment ended on the scheduled date and included 109 patients. Most cases (54%) were performed at 3 centres, where more than 10 THP each were implanted (10–26). The observed mortality in the large-volume centres (22%) was comparable to that observed in the low-volume centres (20%). The individually risk-adjusted cumulative sum revealed that observed in-hospital mortality was statistically in line with that predicted by the log EuroSCORE. Analysis of the secondary end point revealed 8% cases of paraplegia, all of which appeared after treatment of the thoracic type A aortic dissection. CONCLUSIONS: In France, THP for emergency frozen elephant trunk surgery outside high-volume centres did not result in excessive in-hospital deaths. However, a word of caution must be expressed regarding the prevention of medullar ischaemia even in emergency aortic surgery.
- 3 November 2020
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 59 (2) , 458-466
The frozen elephant trunk technique in an emergency: THORAFLEX French National Registry offers new insights
OBJECTIVES: Our goal was to study the immediate outcome after an emergency frozen elephant trunk procedure with a Thoraflex™ Hybrid prosthesis (THP) in patients included in the EPI-Flex national registry and operated on in 21 French centres. METHODS: All patients operated on in France between April 2016 and April 2019 for acute aortic syndromes and who had an frozen elephant trunk procedure with a THP were included in the study. The main end point was in-hospital mortality. The secondary end point was neuromorbidity, including paraplegia. The evolution of the main end point was monitored using a variable life-adjusted display graph with cumulative sum derivatives in order to stop inclusions in case the observed mortality became out of range compared to an expected mortality between 15% and 20%. RESULTS: Enrolment ended on the scheduled date and included 109 patients. Most cases (54%) were performed at 3 centres, where more than 10 THP each were implanted (10–26). The observed mortality in the large-volume centres (22%) was comparable to that observed in the low-volume centres (20%). The individually risk-adjusted cumulative sum revealed that observed in-hospital mortality was statistically in line with that predicted by the log EuroSCORE. Analysis of the secondary end point revealed 8% cases of paraplegia, all of which appeared after treatment of the thoracic type A aortic dissection. CONCLUSIONS: In France, THP for emergency frozen elephant trunk surgery outside high-volume centres did not result in excessive in-hospital deaths. However, a word of caution must be expressed regarding the prevention of medullar ischaemia even in emergency aortic surgery.
- Open Access
- 1 April 2019
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 129, 2-12
Activation of the calcium-sensing receptor in human valvular interstitial cells promotes calcification
- 1 April 2019
- Published by Elsevier in Journal of Molecular and Cellular Cardiology
- Vol. 129, 2-12
Open AccessActivation of the calcium-sensing receptor in human valvular interstitial cells promotes calcification